Dow Jones Newswires: GlaxoSmithKline to buy Sierra Oncology for $1.9 billion


By Ian Walker

Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.

GlaxoSmithKline will pay $55 per share in cash, a 39% premium to its closing price of $39.52 on Tuesday. The deal has the support of Sierra’s board as well as shareholders owning 28% of its stock.

Glaxo reaffirmed its guidance. It expects 2021-2026 sales growth of more than 5% and for 10% adjusted operating profit.

The deal is expected to close in the third quarter of this year.

Write to Ian Walker at

Mark Hulbert: Investors are fearful now, but for stocks to rally they’ll need more pain. It’s coming.

Previous article

Dow Jones Newswires: IEA cuts demand forecast and says reserve release will help counter loss of Russian supplies

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News